Rheumatoid Arthritis Interstitial Lung Disease: Measuring and Predictive Factors Among Patients Treated in Rehabilitation Clinics at Royal Medical Services

Abstract

Introduction: Autoimmune diseases have increasing importance in modern medicine and cover increasing areas of medicine including rheumatoid arthritis interstitial lung disease. Aim: The main aims of this study are to evaluate the association of some autoimmune variables in patients with rheumatoid arthritis interstitial lung disease. Methods: A retrospective study was conducted from files of patients with rheumatoid arthritis interstitial lung disease. A total of 210 files of intended patients were included in this study. The study was conducted in rehabilitation clinics at Royal Medical Services. Study variables include some demographic variables such as age, and gender; clinical variables such as disease related factors such as duration, diagnostic criteria; predictive factors such as rheumatoid factors, smoking, and MTX treatment. Data were collected and entered into excel spreadsheet to create raw data. The analysis of data was carried out using the software SPSS version 21. Descriptive statistical parameters were used to describe data including means and standard deviations for continuous variables. Frequency and percentages were used to describe categorized variables such as gender. The relationships between study variables were computed using independent T test, and One Way ANOVA test. Significance was determined if α≤ 0.05. Results: The prevalence of RA-ILD was 3.70%. The study participants were subdivided into two groups according to MTX treatment, non-exposed group and exposed group. There were significant relationships between MTX treatment and study variables including gender, age of (rheumatoid arthritis) RA onset, smoking, and rheumatoid factor (RF). The progression of RA-ILD was impacted by gender, age of (rheumatoid arthritis) RA onset, smoking, rheumatoid factor (RF), and MTX treatment. Conclusion: Patients with RA and RA-ILD follow similar clinical characteristics in other studies except MTX treatment, but this can’t be generalized because of small number of RA-ILD patients.

Epidemiology and clinical characteristics of interstitial lung disease in patients with rheumatoid arthritis from the JointMan database

“…In this study, assessment of the clinical characteristics of patients in the RA and RA-ILD cohorts showed that patients with ILD were more likely to be older, male, have a history of COPD, and have more prominent RA [16][17][18][25][26][27][28][29] , we confirmed baseline COPD 30 , and baseline moderate-to-high CDAI score, and CRP > 5 mg/L as risk factors. Although smoking is an established risk factor for RA-ILD 25,31 , in our analysis, differences in baseline smoking prevalence were not significant based on statistical testing. However, it should be noted that identification of smoking exposures in patient data www.nature.com/scientificreports/ is limited by missingness, and there may have been a large proportion of false negatives, which would limit reliability.…”

“…A higher proportion of patients with RA–ILD had Medicare insurance when compared with the RA cohort; this can be at least partially explained by the age difference, as a larger proportion of patients with RA–ILD were over the age of 65 when compared with the RA cohort. Potential risk factors for RA–ILD were further analyzed by a Cox regression model and, in addition to older age and seropositivity, which are already established risk factors 16 – 18 , 25 – 29 , we confirmed baseline COPD 30 , and baseline moderate-to-high CDAI score, and CRP > 5 mg/L as risk factors. Although smoking is an established risk factor for RA–ILD 25 , 31 , in our analysis, differences in baseline smoking prevalence were not significant based on statistical testing.…”

“…Potential risk factors for RA–ILD were further analyzed by a Cox regression model and, in addition to older age and seropositivity, which are already established risk factors 16 – 18 , 25 – 29 , we confirmed baseline COPD 30 , and baseline moderate-to-high CDAI score, and CRP > 5 mg/L as risk factors. Although smoking is an established risk factor for RA–ILD 25 , 31 , in our analysis, differences in baseline smoking prevalence were not significant based on statistical testing. However, it should be noted that identification of smoking exposures in patient data is limited by missingness, and there may have been a large proportion of false negatives, which would limit reliability.…”

“…A study, similar to that reported here, using the United States-based Truven Health MarketScan Commercial and Medicare Supplemental health insurance databases, showed the prevalence of RA–ILD in the US was 3.2 to 6.0 cases per 100,000 people 4 . A retrospective review of patient data in Jordan found prevalence of RA–ILD among 210 patients to be 3.7% 25 . It is important to note that the study reporting an RA–ILD prevalence at the higher end of the range of 58% was a small analysis of 36 patients with early RA (duration < 2 years); the prevalence estimate included both patients with “clinically significant ILD” and with “abnormalities compatible with ILD but no clinically significant ILD” 9 .…”

Relationship between the Degree of Illness in Elderly Patients with Rheumatoid Arthritis and Parameters of Musculoskeletal Ultrasound and Oswestry Dysfunction Index and Clinical Value Analysis

“…According to relevant literature, the incidence of RA is the highest in systemic connective tissue disease mostly in women aged 35–55 years old, with the incidence as 0.49%, and the incidence and disability rate of RA increase with age [ 4 ]. According to statistics, the number of patients with RA accounts for about 0.99% of the global population, with the prevalence rate in China at about 0.29%, and the ratio of male to female morbidity is about 1 : 2.4 [ 5 ]. Skielta Mattias et al [ 6 ] have noted that the 4–9 years of mutilation rate is about 59.99% if RA patients do not receive timely treatment, and the disability rate over 25 years is 89.99%, which seriously affects the health of patients.…”